Cardiac mapping and navigation have become a crucial part of evaluating patient’s electro-anatomical data which is obtained so that the electrophysiologists can have a better understanding of underlying cardiac arrhythmia disorders. In the recent years, the revolution in the field of medical science has led to the development of technically advanced cardiac mapping and navigation systems which has the capability to collect 3D placements of the electrical activity of cardiac chambers in order to achieve a specific picture of the heart’s electrical sequence. The mapping and navigation systems developed and employed to date have revolutionized the clinical electrophysiology laboratory and their use has led to numerous novel insights into underlying arrhythmia mechanisms.
According to IQ4I estimation, Cardiac electrophysiology mapping, navigation and recording devices global market is expected to grow at a high single digit CAGR to reach $1,447.3 million by 2024. North American region held the largest market share in 2017 whereas, Asia-Pacific region is projected to grow with a strong CAGR. The Cardiac EP mapping, navigation and recording devices global market is segmented into mapping and navigation systems, mapping and navigation catheters, recording systems and accessories based on the Products. Cardiac mapping and navigation catheters are used to diagnose the irregular or abnormal heartbeat by determining the areas of the heart chambers that interfere in the normal functioning of the heart’s electrical system and enabling better diagnosis and treatment of complex arrhythmias that may be inefficient using other conventional mapping systems like ECG.
According to American Heart Association 2.7million people are living with atrial fibrillation(one of the major types of arrhythmia) in 2017 and according to British Heart Rhythm Society nearly 3million people have arrhythmia in U.K out of which 1.5 million suffer from atrial fibrillation. Increasing number of patients with arrhythmia, increase in research and development activities, increase in minimally invasive technologies for atrial fibrillation are some of the factors driving the market. The inaccuracy of the imaging systems due to body movements, the high cost of electrophysiology mapping and navigation devices, exposure to harmful radiations from the devices are some of the restraints of the market.
Cardiac electrophysiology mapping, navigation and recording devices have huge potential to replace ECG and other diagnostic devices in the diagnosis of arrhythmia due to accuracy of the mapping and navigation systems, improved success, and fewer complications which have led to widespread acceptance of Cardiac EP mapping, navigation and recording devices. In the diagnosis and treatment of complex arrhythmias, such as atrial fibrillation, ventricular tachycardia, atrial flutter the Electro-anatomical mapping and navigation system have many advantages. Firstly, the mapping catheter renders point-to-point positions of spatial coordinates thus creating a three dimensional (3D) anatomy of the cardiac chamber, the information about the electrical activity within the heart could be acquired by fluoroscopy-free catheter navigation. Secondly, the mapping and navigation system help in the determination of the mechanism of tachycardia as focal re-entrant and also identifies the targeted sites for ablation.
Advancements in mapping technologies like non-contact mapping, high resolution imaging, 3D mapping and real-time patient monitoring are the emerging trends. These advanced technologies give a better understanding in the diagnosis of electroanatomy of heart chambers and record the origin of electric signals during an EP procedure in order to accurately ablate arrhythmias. For instance, Johnson and Johnson’s CARTO 3 mapping system, an advanced imaging technology that utilizes electromagnetic technology to create real-time three-dimensional (3D) maps of a patient’s cardiac structures. CardioInsight systems from Medtronic, PLC is a non-contact mapping system with a disposable multi-electrode vest which is used to collect electrical signals from the surface of patient’s cardiac chamber and displays activation, composite and phase 3D color maps.
The Cardiac EP mapping, navigation and recording devices global market is a highly consolidated and the top four players occupy significantly high share. Johnson & Johnson (Biosense Webster) (U.S.), Abbott Laboratories (St Jude Medical) (U.S.), GE Healthcare (U.S.), Boston Scientific (U.S.) are the major players. Other key players in the market are Medtronic PLC (Ireland), Stereotaxis, Inc. (U.S.), Acutus Medical (U.S.), Auris Surgical Robotics (Hansen Medical), Microport Scientific Corporation (China), Magnetecs Corporation (U.S.).
APN Health (U.S.), Kardium (U.S.), EP Solutions (Switzerland) and Pulmokard Gmbh (Germany) are some of the emerging players in the Cardiac EP mapping, navigation and recording devices market.
For any further information please visit our website: https://www.iq4i.com/reports-category/medicaldevices/r/177
You can write to us: firstname.lastname@example.org